04 · Five things to know · 05

AbbVie took an option on AND-gated bispecifics from DISCO; Bloomberg reports Sanofi is weighing a bid for Insmed

Erasca says 44% of 25 responded; it’s Phase 1 · No. 052 · · About 1 min read

Know it

What happened

AbbVie and DISCO Pharmaceuticals agreed on 11.19 to a research collaboration with an option to license AND-gated bispecific antibodies for solid tumors, which aim to act only on cells carrying two antigens. DISCO gets $40M upfront and is eligible for up to $2.5B in option, development and other milestones, plus royalties; targets were not disclosed. AbbVie Ventures is an existing investor in DISCO, a company in Cologne, Germany, which closed a €36M seed round in December 2025. Separately, Bloomberg reported, citing unnamed people, that Sanofi is weighing a takeover bid for Insmed. No price was reported, Insmed declined to comment, and no deal has been announced. Claim

The DISCO upfront is small next to its milestones, so most of the headline value depends on future options. A reported interest in a deal is not a deal. Analysis

Sources

Bookmarks need a Mind Club sign-in. How sign-in works

Read it in Five things to know